Biomarkers /
FANCG
Overview
Fanconi anemia, complementation group G (FANCG) is a gene that encodes a protein that is a member of the Fanconi anemia complementation group. The protein complex functions in the heterogeneous recessive disorder Fanconi anemia that causes cytogenetic instability, hypersensitivity to DNA crosslinking agents, increases chromosomal breakage, and defective DNA repair. Missense, nonsense, and silent mutations are observed in cancers such as endometrial cancer, intestinal cancer, and stomach cancer.
FANCG is altered in 1.33% of all cancers with lung adenocarcinoma, colon adenocarcinoma, melanoma, breast invasive ductal carcinoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in FANCG are FANCG Mutation (1.10%), FANCG Amplification (0.19%), FANCG X494_splice (0.04%), FANCG A265V (0.04%), and FANCG A607T (0.06%) [3].
Clinical Trials
Significance of FANCG in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.